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ABSTRACT
RELEASE KINETICS OF METRONIDAZOLE FROM 3D PRINTED SILICONE
SCAFFOLDS
Sydney Herold
April 4, 2022

Sustained local administration of active agents has been proposed to cure bacterial
vaginosis in the female reproductive tract and restore the resident bacterial fauna.
Bioprinting has shown promise for the development of systems for local agent delivery. In
contrast to oral ingestion, agent release kinetics can be fine-tuned by bioprinting
specialized scaffold designs tailored for particular treatments while enhancing dosage
effectiveness via localized sustained release. It has been challenging to establish scaffold
properties for sustained release as a function of fabrication parameters. Towards this goal,
we evaluate 3D printed scaffold formulation and feasibility to sustain release of
metronidazole, a representative antibiotic. Silicone scaffolds were printed in a cylindrical
design and cured using three different conditions relevant to potential future incorporation
of temperature-sensitive labile biologics. Scaffold A was cured 4 hr at 50oC followed by
72 hr at 4oC, while Scaffold B was cured 4 hr at 50oC followed by 24 hr desiccation at
room temperature and Scaffold C was cured 24 hr at 50oC. Drug release and compressive
strength were monitored for 14 d in simulated vaginal fluid to assess long-term effects of
fabrication conditions on release kinetics and mechanical integrity. Release profiles were
v

fitted to previous kinetic models to differentiate potential release mechanisms. Scaffold A
released 54.1% of drug over 14 d compared to 40.8% for Scaffold B and 33.7% for Scaffold
C. Of six models evaluated, the Higuchi, Korsmeyer-Peppas, and Peppas-Sahlin models
best described the release, indicating similarity to release from insoluble or polymeric
matrices. All scaffolds were axially and radially compressed to determine compressive
strength and compressive Young’s modulus. For all metronidazole-containing scaffolds,
similar axial and radial compression was observed between post-cure and 24 hr and 14 d
groups. We conclude that 3D printed silicone scaffolds can provide sustained
metronidazole release over 14 d, with release kinetics and compressive strength tuned by
the fabrication parameters.
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NOMENCLATURE
3D

3-Dimensional

BV

Bacterial vaginosis

EVAc

Ethylene-vinyl acetate copolymer

FTR

Female reproductive tract

HIV

Human immunodeficiency virus

IVR

Intra-vaginal ring

STI

Sexually transmitted disease

SVF

Simulated vaginal fluid
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I. INTRODUCTION

Bacterial vaginosis (BV) is a common vaginal infection diagnosed in
approximately 1 in 3 women of reproductive age in the U.S.1. BV results from a loss of
healthy, lactic acid producing, lactobacilli and an increase in facultative and anaerobic
bacteria in the vagina1-3. One of the prominent anaerobes associated with BV is
Gardnerella vaginalis, a pH-sensitive bacterium that grows well in slightly acidic pH but
is unable to grow in the low pH of the healthy female reproductive tract (pH 4.5) 3,4.
Symptoms of BV include discoloration and malodorous discharge, vaginal itching and
burning2,5. However, more severe long-term afflictions can present, resulting in a variety
of pregnancy complications, preterm delivery, and an increased susceptibility to HIV and
other sexually transmitted infections (STIs)1.
The current standard of treatment for women diagnosed with BV is a 5d to 7d oral
or topical regimen with an antibiotic such as metronidazole, with twice daily oral regimens
or once-daily intravaginal gel application for 5d to 7 d6,7. Topical administration has been
shown to be advantageous as it avoids the adverse effects related to oral administration
while allowing localized drug release directly at the site of infection. Moreover, a variety
of dosage forms, including vaginal gels, suppositories, nanoparticle-based systems, and
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intravaginal rings (IVRs) have been used to administer antibiotics and other active agents
in efforts to topically eliminate a variety of intravaginal infections8-14. Yet, with the
exception of IVRs, these dosage forms act transiently and necessitate frequent daily
administrations to exert therapeutic effect. Furthermore, the leakage and associated
messiness associated with current dosage forms can result in a lack of user adherence and
compliance, which in turn can promote antibiotic-resistance and non-specific elimination
of commensal bacteria, ultimately leading to recurrent infections. As an alternative
strategy, probiotics have demonstrated success in restoring vaginal flora and reestablishing
a healthy acidic pH making the vaginal environment less hospitable to the colonization of
pathogens such as G. vaginalis. However, much like antibiotic dosage forms, there are a
dearth of topical probiotic or combination dosage forms that provide sustained or phased
co-delivery of one or more active agents to reduce recurrent bacterial (and viral) infections.
One of the few dosage forms that has demonstrated success in attaining long-term
intravaginal delivery is intravaginal rings. A variety of polymers including silicone,
polyurethanes, and ethylene vinyl acetate (EVAc) have been used to facilitate the release
of hydrophobic molecules, such as hormones, and more recently antibiotics, such as
metronidazole, for intravaginal applications15,16. Silicone, in particular, has been shown to
have exceptional biocompatibility, low surface tension for uniform drug distribution, as
well as biodurability in low pH environments17. However, IVR fabrication typically relies
on molding techniques that can be susceptible to deformation and contamination, in
addition to harsh solvents, temperatures, and multistep fabrications that may be less
amenable to the inclusion of more labile biologic agents18.
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A proposed solution to improve upon the duration of administration, multitherapeutic compatibility of manufacturing, and throughput of the fabrication process, is to
utilize extrusion-based 3D printing. Extrusion-based 3D printing, in combination with
computer aided design, can be used to fabricate architectures with discrete compartments
to facilitate the release of different active agents from sequentially-printed layers19. These
features enable the fabrication of simple and complex architectures that can provide
personalized dosing with sustained release and increased bioavailability of drug at a
localized site. One notable example is the polypill, PolycapTM, which is commercially
available to treat hypertension and cardiovascular disease20,21. Through the development
of the polypill, 3D printing has shown promise in producing consistent complex geometric
designs with multiple drug formulations. While 3D printing has been utilized for a few
vaginal applications22-27, it has not been extensively studied for vaginal drug delivery.
While 3D printing has the potential to provide a novel and efficacious alternative
dosage form for reproductive health, a variety of factors including material properties,
scaffold architecture, and post-print processing can affect the dosage form design and
resulting release properties. Design optimization can require numerous experimental
iterations depending on the critical parameters of interest. Complementing formulation
development with mathematical modeling enables the knowledge of physical parameters,
such as drug diffusion coefficients and polymer relaxation coefficients, to be combined
with mathematical equations representing a given system, to help establish, predict, and
validate parameters integral to achieving design criteria. In particular, mathematical
modeling may be useful in establishing key outcomes, such as release kinetics, mechanical
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integrity, and degradation as a function of the post-processing conditions of new 3D printed
dosage forms.
In this study, one of the key considerations to the 3D printed scaffold design was
the ability to prolong metronidazole release for durations of one week or longer.
Additionally, since we seek to design future scaffolds to co-deliver other active agents,
including more labile biologics, the duration and temperature of post-print processing were
primary parameters of interest in enabling sustained release. With this long-term goal in
mind, we considered the effect of scaffold curing temperature and time on metronidazole
release.
We fabricated three different 3D printed silicone scaffold formulations, which
varied in their post-print curing conditions, and evaluated in vitro drug release in simulated
vaginal fluid (SVF). One formulation included a post-print cure for 4 hr at 50°C, followed
by incubation for 72 hr at 4°C to enhance the mechanical integrity of the scaffold. An
additional formulation included a post-print cure for 4 hr at 50°C followed by incubation
at room temperature (20°C) for 24 hr. Similar to the first formulation, these curing
conditions aimed to enhance the mechanical integrity of the scaffold while minimizing the
scaffold time spent at room temperature. Metronidazole-containing scaffolds cured for 24
hr at 50oC (Scaffold C) had the highest compressive strength immediately post cure,
however following 14 d immersion in SVF scaffolds cured for 4 hr at 50oC followed by 72
hr at 4oC (Scaffold A) had the highest compressive strength.
In parallel, we utilized mathematical modeling to evaluate the impact of post-print
curing on antibiotic release kinetics. Potential mechanisms of drug release were assessed
via established kinetic models, including zero order, first order, Higuchi, Korsmeyer4

Peppas, Hixson-Crowell, and Peppas-Sahlin28. The modeling was employed to provide
evidence that the formulated scaffolds release metronidazole via diffusion-controlled
release from silicone, in order to validate our drug delivery system as a viable treatment
for sustained intravaginal delivery.

5

II. MATERIALS AND METHODS

A. Materials

A mixture of Part A: vinyl-terminated polydimethylsiloxane (70%, PDMS) and
vinyl, methyl-modified silica (30%) and Part B: trimethylsiloxane-terminated
methylhydrosiloxane-dimethylsiloxane copolymer, were purchased from Allevi, Inc.
(Philadelphia, PA). Dimethyl sulfoxide (DMSO, Fischer Scientific, B231-1), and
Metronidazole (Sigma Aldrich, M3761-5G) were used to formulate the bioink. Simulated
vaginal fluid (SVF) was prepared as mentioned in29,30.

B. Synthesis of 3D Printed Silicone Scaffolds Containing Metronidazole

1. Synthesis of Printable Silicone Ink

3D printed scaffolds were formulated from a mixture of Part A:Part B and
metronidazole. Briefly, metronidazole (55 mg) was weighed, ground to a fine powder with
a mortar and pestle, and added to a microcentrifuge tube containing 60 𝜇L DMSO. The
silicone consisting of 1.0 g:0.1 g of Part A:Part B PDMS, respectively, was then added to
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the microcentrifuge tube and vortexed to ensure homogeneity. The ink was then vigorously
mixed with a spatula for a minimum of 5 minutes.

2. Printing Scaffolds
A 1 mL aliquot of metronidazole “ink” was loaded into a 5 mL syringe and placed
into the CORE head of the Allevi 3 Bioprinter. A customized Stereolithography (STL) file
was created in the form of a cylindrical capsule. The capsule dimensions were sized for a
mouse model of BV: 5 mm in height, 4 mm in diameter, with a shell thickness of 0.5 mm.
The Allevi 3 Bioprinter was used to 3D print all scaffolds. The extrusion pressure was set
at 100 psi, the CORE head of the extruder was set at 30°C, and the extrusion flow rate was
set at 5 mm/sec The layer height for printing was set at 0.2 mm, the infill distance was
fixed at 0.35 mm with zig-zag infill type, and a 23G needle gauge was used for extruding
the formulated bioink. Scaffolds were printed in a petri dish using the STL file as a printing
template and were then subjected to one of three different post-print curing conditions.

3. Curing and Storage Time/Conditions

Three different 3D printed silicone scaffold formulations were fabricated, with
variations in their post-print curing conditions. Scaffold A was cured in an oven at 50°C
for 4 hr, followed by incubation at 4°C for 72 hr. The curing conditions established for this
scaffold consider the potential of future biologic inclusion by attempting to minimize high
temperature exposure which can lead to biologic inactivation31,32. Scaffold B was cured at
50°C for 4 hr, followed by incubation at 20°C for 24 hr which sought to improve the
mechanical integrity of the scaffold while minimizing duration of exposure to temperatures
7

higher than 50°C. Scaffold C was cured at 50°C for 24 hr to provide the most mechanically
sound structure, per the conventional Allevi printing protocol.

4. Metronidazole Incorporation

A metronidazole concentration of 50 µg/mg was selected for initial loading as this
concentration was found to eliminate anaerobes including, G. vaginalis, Prevotella species,
and Bacteroides species based upon their MIC50 values (< 8 µg/mL), and the susceptibility
breakpoint concentration for metronidazole defined by the Clinical and Laboratory
Standards Institute (CLSI). In comparison, commensal lactobacilli have a MIC50 >128
µg/ml for metronidazole, enabling some level of evaluation with treatment33-39. The
theoretical loading (µg) of each scaffold was calculated based on the scaffold weight and
the concentration of metronidazole in the silicone ink (Eq. 1).

𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝐿𝑜𝑎𝑑𝑖𝑛𝑔 (µ𝑔) = 𝑆𝑐𝑎𝑓𝑓𝑜𝑙𝑑 𝑀𝑎𝑠𝑠 (𝑚𝑔) ∗ 𝐷𝑟𝑢𝑔 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (µ𝑔/𝑚𝑔)

(1)

C. Drug Release Studies

In vitro drug release was evaluated in SVF. The prepared metronidazole-containing
silicone scaffolds were submerged in 5 mL of SVF (pH 4.2) and incubated at 37oC to mimic
physiological temperature. Metronidazole release was evaluated at 2, 4, 8 hr, and after 1,
2, 3, 4, 5, 6, 7, 8, 9, 10, and 14 d. At established times, SVF was removed from the 5 mL
tubes, scaffolds were washed with 1x PBS, and fresh SVF was added. The amount of
metronidazole in each eluate sample was determined by reading absorbance (320 nm, Gen
5 app, BioTek Synergy H1 Microplate Reader) and correlating with a metronidazole
8

standard curve. The cumulative release of metronidazole was calculated as the µg of
metronidazole released per mg scaffold and as the % total loaded shown in Eq. 2.

% 𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝐷𝑟𝑢𝑔 𝑅𝑒𝑙𝑒𝑎𝑠𝑒 =

[𝐷𝑟𝑢𝑔]𝑡
[𝐷𝑟𝑢𝑔]𝑡𝑜𝑡𝑎𝑙

∗ 100

(2)

where [𝐷𝑟𝑢𝑔]𝑡 refers to the amount of drug release at time 𝑡 and [𝐷𝑟𝑢𝑔]𝑡𝑜𝑡𝑎𝑙 refers to the
total amount of drug loaded into the scaffold.

D. Mechanism of Drug Release

To assess the mechanism of drug release, representative kinetic models were used
to analyze the release data based on previous modeling efforts that incorporated
metronidazole. The zero order kinetic model describes drug release independent of drug
concentration in solution (Eq. 3)40,

𝑄𝑡 = 𝑄0 + 𝑘𝑡

(3)

where 𝑄𝑡 is the amount of drug dissolved in time 𝑡, 𝑄0 is the initial amount of drug in
solution, and 𝑘 is the zero order rate constant. The first order kinetic model describes drug
release dependent on drug concentration (Eq. 4)40,

𝑘𝑡

𝑙𝑜𝑔𝐶 = 𝑙𝑜𝑔𝐶0 − 2.303
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(4)

where 𝐶 is drug concentration at time 𝑡, 𝐶0 is initial drug concentration, and 𝑘 is the first
order rate constant. The simplified Higuchi model describes drug release from polymeric
systems, where dissolution is the main method of drug transfer (Eq. 5)41.

𝑀𝑡
𝑀∞

= 𝑘 √𝑡

(5)

where 𝑀𝑡 /𝑀∞ is the cumulative amount of drug released at time 𝑡, and 𝑘 is the Higuchi
rate constant, also known as the diffusion coefficient. The Korsmeyer-Peppas model
describes drug release from polymeric matrices (Eq. 6)40.

𝑀𝑡
𝑀∞

= 𝑘′𝑡𝑛

(6)

where 𝑀𝑡 /𝑀∞ is the cumulative drug release at time 𝑡, 𝑘′ is the drug release coefficient,
and 𝑛 describes a mechanism of diffusion. The Hixson Crowell cube root model utilizes
the proportionality of a particle's area to its volume to describe drug release (Eq. 7)42,

𝑊01/3 − 𝑊𝑡 1/3 = 𝑘𝑡

(7)

where 𝑊0 is the initial amount of drug, 𝑊𝑡 is the remaining amount of drug at time 𝑡, and
𝑘 is the rate rate constant. The Peppas-Sahlin model accounts for the effects of Fickian
diffusion and polymer chain relaxation when describing drug release (Eq. 8)43,
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𝑀𝑡
𝑀∞

= 𝑘𝑑 𝑡 𝑚 + 𝑘𝑟 𝑡 2𝑚

(8)

where 𝑀𝑡 /𝑀∞ is the cumulative drug release at time 𝑡, 𝑘𝑑 is the kinetic constant associated
with Fickian diffusion, 𝑘𝑟 is the kinetic constant associated with polymer chain relaxation,
and 𝑚 is the purely Fickian diffusion exponent43.
Each model’s adequacy was evaluated using MATLAB Curve Fitting Toolbox.
Once the parameters were obtained, graphs were constructed using Microsoft Excel. All
models were obtained by plotting cumulative percent drug release against time and using
the Custom Equation option to fit the model to the data.

E. Mechanical Testing
The compressive strength and Young’s modulus of the scaffolds were evaluated as
a function of curing condition. Blank silicone and metronidazole-containing silicone
scaffolds were assessed after curing with the following conditions: 50°C for 4 hr, followed
by incubation at 4°C for 72 hr; 50°C for 4 hr, followed by incubation at 20°C for 24 hr;
and 50°C for 24 hr (Scaffold A, B, and C, respectively). Scaffolds were assessed
immediately post-cure, and after 24 hr or 14 d in SVF.
Axial and radial compression was measured using the Instron 5569 testing system,
and data were extrapolated using Instron Bluehill software (Norwood, MA). Compression
test parameters were selected to represent the range with which commercial IVRs have
been tested44-46. A 5 kN load cell was used, and the applied force was varied between 0.6
and 1.6 N. The transducer was lowered to the scaffold surface prior to the test and
transducer displacement was set to 1 mm with a displacement rate of 1 mm/min. These
11

configurations are equivalent to 20% or 25% compression in the axial and radial directions,
respectively.

F. Statistics

Drug release and compression measurements were performed using a minimum of
n=3 samples per run. Error bars denote standard deviation (SD), and results are reported as
the mean ± SD. The software Minitab was used to statistically analyze metronidazole
release from 3D printed silicone scaffolds. A Grubbs’ test was utilized to determine the
presence of outliers (p ≤ 0.05). Statistical significance between the final release values, as
a function of curing condition, was verified using a paired t-test (p ≤ 0.05). One-way
ANOVA was used to evaluate the mechanical testing results and determine the statistical
significance between scaffolds.
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III. RESULTS

A. Drug Release from 3D Printed Silicone Scaffolds

The tested 3D-printed scaffold design is shown in Figure 1.
Metronidazole was completely dissolved in silicone during the fabrication of the
printable silicone ink to evaluate drug release kinetics. The cumulative release of
metronidazole is shown as a function of percent of total loading (Figure 2). Overall, the
3D printed silicone scaffolds showed a steady release of metronidazole within the first 6
hr, following a common trend observed with small molecules6,28,47,48. Post-print curing
condition proved to have an effect on cumulative release. Scaffold A showed the highest
metronidazole release, with 15.8±2.4% release occurring in the first 24 hr, followed by a
steady increase to 54.1±2.9% after 14 d. Scaffold B showed intermediate levels of release,
with 10.2±0.8% of drug released during the first 24 hr and 40.8±4.1% after 14 d. Scaffold
C showed the least overall release with 8.7 ± 2.4% release over the first 24 hr and only
33.7±5.1% release after 14 d. For short-term (24 hr) and long-term (14 d) drug release,
statistical significance (p ≤ 0.05) was observed between Scaffolds A and B and between
Scaffolds A and C, however release from Scaffolds B and C were not statistically
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significant. The post-print curing condition of Scaffold A (4 hr at 50oC followed by 72 hr
at 4oC) provided enough mechanical integrity to extend drug release over 14 d.
Accordingly, this formulation may be a promising curing condition to use for eventual
inclusion of more labile biologics.

B. Kinetic Models of Drug Release

Previously developed mathematical kinetic models are useful to evaluate potential
mechanisms of drug release, and they were applied here to study metronidazole release
from the 3D printed silicone scaffolds. For each scaffold formulation, in vitro release
curves (Figure 2) were fitted to various representative kinetic models to describe potential
mechanisms of release (Figures 3-5).
The resulting correlation values and rate constants for all models are summarized
in Table 1.
Each model exhibited similar R2 values across the three different post-print curing
conditions; therefore, the most appropriate condition can be selected without it affecting
the mechanism of metronidazole release. The Higuchi, Korsmeyer-Peppas, and PeppasSahlin models best described the release of metronidazole from the 3D printed silicone
scaffolds. The Higuchi model had an R2=0.9918 (Scaffold A), R2=0.9955 (Scaffold B), and
R2=0.9954 (Scaffold C). The Korsmeyer-Peppas model had an R2=0.9931 (Scaffold A),
R2=0.9959 (Scaffold B), and R2=0.9958 (Scaffold C). Lastly, the Peppas-Sahlin model had
an R2=0.9990 (Scaffold A), R2=0.9990 (Scaffold B), and R2=0.9980 (Scaffold C). This
indicates that the release of metronidazole, a hydrophobic drug, from silicone, a
hydrophobic polymer, is best modeled similar to drug release from an insoluble matrix or
14

from a polymeric matrix6,48. The zero order model showed the lowest correlation to
experimental metronidazole release with an R2=0.6862 (Scaffold A), R2=0.7667 (Scaffold
B), and R2=0.7699 (Scaffold C), indicating the release of metronidazole from 3D printed
silicone scaffolds is not independent of drug concentration in solution40,49. This is
confirmed by the first order model showing significantly improved correlation compared
to the zero order model for all post-print curing conditions, although not quite reaching the
performance of the best three models.

C. Mechanical Properties

1. Compression

The load required to compress each scaffold was evaluated as a function of scaffold
curing conditions immediately post-cure, and after 24 hr and 14 d in SVF. All scaffolds
were compressed by 20% of their height and 25% of their diameter, in the axial and radial
directions, respectively.
a. Axial Compression. First the axial compression of blank and metronidazolecontaining scaffolds was assessed (Figure 6). For blank silicone scaffolds, the load
required to axially compress scaffolds immediately post-cure and after 24 hr in SVF
(Figure 6A-C) was lower after curing for 4 hr at 50°C (Scaffolds A and B) compared to
scaffolds cured for 24 hr at 50°C (Scaffold C, p ≤ 0.0001). However, all blank scaffolds
exhibited similar axial compression following 14 d immersion in SVF (p > 0.05).
Within each blank scaffold group (A, B, or C), the load required to achieve axial
compression was similar between post-cure and 24 hr cure groups (p > 0.05); however,
15

increased between post-cure and 14 d groups (Scaffolds A, B, C: p ≤ 0.01; p ≤ 0.0001; p
≤ 0.05) (Figure 6A-C). Additionally, scaffolds cured for 4 hr at 50°C (Scaffolds A and B)
showed increased loads required to compress scaffolds immersed for 24 hr and 14 d
(Scaffolds A, B: p ≤ 0.01; p ≤ 0.001), while scaffolds cured for 24 hr at 50°C (Scaffold
C) required similar loading to achieve compression (p > 0.05).
For metronidazole-containing scaffolds, the load required to axially compress
scaffolds immediately post-cure was lower after curing for 4 hr at 50°C (Scaffolds A and
B) compared to scaffolds cured for 24 hr at 50°C (Scaffold C; Scaffolds A, B: p ≤ 0.05; p
≤ 0.01). All metronidazole-containing scaffolds exhibited similar axial compression
following 24 hr immersion in SVF (p > 0.05). Finally, the load required to axially compress
scaffolds after 14 d immersion in SVF was largest for Scaffold A (cured for 4 hr at 50°C
followed by 72 hr at 4°C) compared to Scaffolds B and C (Scaffolds B, C: p ≤ 0.01; p ≤
0.001).
Within each metronidazole-containing scaffold group and similar to blank
scaffolds, the loads required to axially compress all metronidazole-containing post-cure
and 24 hr scaffold groups were similar (p > 0.05) (Figure 6D-F). The axial compression
load only increased between post-cure and 14 d groups for scaffolds cured for 4 hr at 50oC
(Scaffolds A and B, p ≤ 0.0001), while axial compression was similar between the postcure and 14 d groups cured for 24 hr at 50oC (Scaffold C, p > 0.05). Additionally, the axial
compression load increased between 24 hr and 14 d groups for all metronidazolecontaining scaffolds (Scaffolds A and B, p ≤ 0.0001; Scaffold C, p ≤ 0.01).
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In comparing the load required to axially compress blank, relative to
metronidazole-containing scaffolds, significant effects were observed. Overall, and based
on the average of all immersion conditions for each scaffold type (A, B, or C), the load
required to axially compress blank scaffolds was approximately 8-fold, 12-fold, and 18fold higher for Scaffolds A, B, and C, respectively, than that needed for similar
compression of metronidazole-containing (A, B, or C) scaffolds. These results suggest that
metronidazole incorporation at the specified concentration may weaken the scaffolds under
axial compression.
b. Radial Compression. Following axial compression, all scaffolds were
compressed in the radial direction to account for additional forces the scaffolds may
experience in the vaginal environment. For blank silicone scaffolds, the loads required to
radially compress scaffolds immediately post-cure and after 24 hr in SVF (Figure 7A-C)
were lower after curing for 4 hr at 50°C (Scaffolds A and B; p ≤ 0.01 and p ≤ 0.0001),
relative to scaffolds cured for 24 hr at 50°C (Scaffold C). However, similar to that observed
in axial compression, all blank scaffolds exhibited similar radial compression following 14
d in SVF (p > 0.05).
Within each blank scaffold group (A, B, or C), Scaffolds A and B showed increased
loads needed to achieve radial compression for the 14 d in SVF group, relative to scaffolds
assessed post-cure (Scaffolds A, B: p ≤ 0.05; p ≤ 0.001) and after 24 hr immersion in SVF
(Scaffolds A, B: p ≤ 0.05; p ≤ 0.001), while demonstrating similar compression between
the immediate post-cure and 24 hr in SVF groups (Figure 7A-B, p > 0.05). Within the
blank Scaffold C group (cured for 24 hr at 50oC) radial compression was similar between
post-cure, 24 hr, and 14 d groups (Figure 7C, p > 0.05).
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For metronidazole-containing scaffolds, the load required to radially compress
scaffolds immediately post-cure was lower after curing for 4 hr at 50°C (Scaffolds A and
B) compared to scaffolds cured for 24 hr at 50°C (Scaffold C, p ≤ 0.01). All metronidazolecontaining scaffolds exhibited similar radial compression following 24 hr immersion in
SVF (p > 0.05). Finally, the load required to axially compress scaffolds after 14 d
immersion in SVF was highest for Scaffold A (cured for 4 hr at 50°C followed by 72 hr at
4°C) compared to Scaffolds B (p ≤ 0.001) and C (Figure 7D-F, p ≤ 0.0001).
Within each metronidazole-containing scaffold group, Scaffold A showed a
significant increase in load required to radially compress the 14 d in SVF, relative to both
the immediate post-cure group and 24 hr in SVF group (Figure 7D, p ≤ 0.0001)
Additionally, Scaffold B showed a significant increase in the load required to radially
compress the 24 hr and 14 d in SVF, relative to the immediate post-cure group (Figure 7E,
p ≤ 0.01). In comparison, radial compression was similar for Scaffold C (cured for 4 hr at
50oC), between post-cure and 14 d groups (p > 0.05) and increased between 24 hr and 14
d groups (Figure 7F, p ≤ 0.05).
Last and similar to axial compression observations, the load required to radially
compress blank scaffolds was approximately 21-fold, 25-fold, and 30-fold (for Scaffolds
A, B, and C) higher than that needed for similar compression of metronidazole-containing
scaffolds. These results suggest that metronidazole incorporation at the specified
concentration may weaken the scaffolds under radial compression. Additionally, both
blank and metronidazole-containing silicone scaffolds exhibited lower compressive
strength in the radial direction, relative to the axial direction.
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2. Young’s Modulus

Using compressive stress and strain measurements, the axial and radial Young’s
modulus were obtained as a function of curing conditions (Scaffold A, B, or C)
immediately post-cure, and after 24 hr and 14 d in SVF (Figure 8).
a. Axial Young’s Modulus. Within each blank scaffold group (Scaffolds A, B, or
C), the axial Young’s modulus was similar between post-cure and 24 hr groups (p > 0.05);
however, increased between the post-cure and 14 d groups (Figure 8A) (Scaffolds A, p ≤
0.01; B, p ≤ 0.0001; C, p ≤ 0.05). Additionally, for scaffolds cured for 4 hr at 50oC
(Scaffolds A and B), the axial Young’s modulus increased between 24 hr and 14 d groups
(Scaffold A, B: p ≤ 0.01; Scaffold B, p ≤ 0.001).
As a function of immersion duration (analysis post-cure, 24 hr SVF, or 14 d SVF),
the axial Young’s modulus significantly increased after curing for 24 hr at 50oC (Scaffold
C) for the post-cure (Scaffolds A, B: p ≤ 0.001; p ≤ 0.01) and 24 hr conditions (Scaffolds
A, B: p ≤ 0.0001; p ≤ 0.01), relative to a shorter curing duration of 4 hr at 50oC (Scaffolds
A and B). In comparison, for the 14 d immersion samples, the axial Young’s modulus was
similar across blank scaffolds (A, B, and C, p > 0.05).
For metronidazole-containing scaffolds, the axial Young’s modulus (Figure 8B)
increased between post-cure and 24 hr in SVF groups for Scaffold B (cured for 4 hr at 50oC
followed by 24 hr desiccation at room temperature, p ≤ 0.05), while remaining similar
between post-cure and 24 hr groups for Scaffold A (cured for 4 hr at 50oC followed by 72
hr at 4oC) and Scaffold C (cured for 24 hr at 50oC). Additionally, the axial Young’s
modulus increased for all metronidazole-containing scaffolds between post-cure and 14 d
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groups (Scaffolds A, B, C: p ≤ 0.0001; p ≤ 0.0001; p ≤ 0.05) and between 24 hr and 14 d
groups (Scaffolds A, B, C: p ≤ 0.0001; p ≤ 0.0001; p ≤ 0.001).
As a function of immersion duration, the Young’s modulus of the metronidazolecontaining scaffolds assessed immediately post-cure and cured for 24 hr at 50oC (Scaffold
C) was higher than post-cure assessed scaffolds that were cured for only 4 hr at 50oC
(Scaffolds A, B: p ≤ 0.01; p ≤ 0.001). For the 24 hr SVF immersion group, all
metronidazole-containing scaffolds had similar axial Young’s modulus (p > 0.05). Finally,
for the 14 d group, Scaffold A (cured for 4 hr at 50oC followed by 72 hr at 4oC) had a
higher axial Young’s modulus compared to Scaffolds B (cured for 4 hr at 50oC followed
by 24 hr desiccation at room temperature) and C (cured for 24 hr at 50oC) (p ≤ 0.0001).
b. Radial Young’s Modulus. Similar to axial observations, the radial Young’s
modulus was evaluated as a function of curing conditions immediately post-cure, and after
24 hr and 14 d in SVF (Figure 8C-D). Within each blank scaffold group (Scaffolds A, B,
or C), only scaffolds cured for 24 hr at 50oC (Scaffold C) showed an increase in Young’s
modulus between post-cure and 24 hr conditions (p ≤ 0.01). Additionally for each blank
scaffold group (A, B, and C), the radial Young’s modulus increased between post-cure and
14 d conditions (Scaffolds A, B, C: p ≤ 0.01; p ≤ 0.0001; p ≤ 0.01), while scaffolds cured
for 4 hr at 50oC (Scaffolds A and B) showed additional increases between 24 hr and 14 d
groups (Scaffold A, B: p ≤ 0.05; p ≤ 0.001).
As a function of immersion duration (analysis post-cure, 24 hr SVF, or 14 d SVF),
the radial Young’s modulus of blank scaffolds remained similar across post-cure groups
(Figure 8C, p > 0.05). For the 24 hr in SVF group, scaffolds cured for 24 hr at 50oC
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(Scaffold C) had a higher radial Young’s modulus compared to scaffolds cured for 4 hr at
50oC (Scaffolds A, B: p ≤ 0.0001; p ≤ 0.001). All scaffolds immersed in SVF for 14 d had
similar Young’s modulus.
For metronidazole-containing scaffolds, only Scaffold B (cured for 4 hr at 50oC
followed by 24 hr desiccation at room temperature) showed an increase in radial Young’s
modulus (Figure 8D) between post-cure and 24 hr groups (p ≤ 0.05). However,
metronidazole-containing scaffolds cured for 4 hr at 50oC (Scaffolds A and B) increased
in radial Young’s modulus (Figure 8D) between post-cure and 14 d conditions (Scaffolds
A, B: p ≤ 0.0001; p ≤ 0.01), and between 24 hr and 14 d conditions for Scaffold A (p ≤
0.0001). In comparison, scaffolds cured for 24 hr at 50oC (Scaffold C) showed similar
Young’s modulus across immersion conditions (p > 0.05).
As a function of immersion duration, the radial Young’s modulus of metronidazolecontaining scaffolds cured for 24 hr at 50oC (Scaffold C) and assessed immediately postcure had a higher radial Young’s modulus than scaffolds cured for 4 hr at 50oC (Scaffolds
A and B, p ≤ 0.01). For metronidazole-containing scaffolds assessed after 24 hr immersion
in SVF, all had similar radial Young’s modulus (p > 0.05). Finally, for scaffolds assessed
after 14 d immersion in SVF, Scaffold A (cured for 4 hr at 50oC followed by 72 hr at 50oC)
showed a significant increase in radial Young’s modulus compared to Scaffolds B (cured
for 4 hr at 50oC followed by 24 hr desiccation at room temperature) and C (cured for 24 hr
at 50oC) (p ≤ 0.0001).
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IV. DISCUSSION

In this study, metronidazole-containing 3D printed silicone scaffolds were
fabricated to evaluate sustained release kinetics for the potential treatment of BV.
Metronidazole, as a model hydrophobic active agent, was incorporated into silicone by
dissolving in DMSO and physically mixing50. The drug-incorporated ink was loaded into
a syringe and 3D printed using previously mentioned printing parameters. Three different
post-print curing conditions were evaluated to enhance mechanical integrity prior to
immersing each scaffold in SVF for drug release studies and fitting of release profiles to
representative kinetic models.
The release kinetics of metronidazole have been studied previously, using a wide
variety of computational models, materials, dosage forms. In one study, metronidazole was
incorporated into HPMC, psyllium, and Carbopol to fabricate a floating dosage form to
treat peptic ulcer disease28. Metronidazole release was modeled using similar models to
this study, such as zero-order kinetic, first-order kinetic, Higuchi, Hixson-Crowell, Power
law, and the Weibull model. Metronidazole release from the tablet was best modeled by
the power law, as the release is dependent on Fickian diffusion and polymer relaxation. In
another study, metronidazole was incorporated into mesostructured silica-based materials
to treat bone disease6. Metronidazole release was found to differ based on the addition of
various types of organic groups onto the silica. The drug release was adequately modeled
by the Korsmeyer-Peppas model, which indicated diffusion-controlled release.
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Metronidazole has also been incorporated into alginate beads with calcium silicate acting
as a porous carrier to facilitate release51. Javadzadeh et al. modeled the release of
metronidazole using similar models to this study, and also included linear probability, log
probability, and the reciprocal powered time models. The release was shown to be best
modeled by the reciprocal powered time, Weibull, and log probability models.
Additionally, the use of silicone as a means of drug delivery has been previously
studied and modeled. In one study, ibuprofen and diclofenac were incorporated into a
multi-layered silicon matrix system and the release kinetics were modeled using a
numerical model52. The model parameters included diffusion, effective dissolution rate,
and solubility coefficients. Based on support from experimental data, the fabricated
numerical model could be used to design controlled drug release multi-layer silicone
devices. In another study, dexamethasone was incorporated into silicone and the release
was fitted to a previously derived equation53. The model highlighted the impact that system
geometry, size, and composition may have on the drug release kinetics.
In this study, while post-print curing condition did not show an effect on the
mechanism of metronidazole release from silicone, it proved to have an effect on
cumulative release. After 24 hr, Scaffold A showed the greatest percent drug release at
15.8%, followed by Scaffold B at 10.2%, then Scaffold C at 8.7%. After 14 d, Scaffold A
released 54.1% of drug, relative to 40.8% for Scaffold B and 33.7% for Scaffold C. Due to
the hydrophobicity of metronidazole, none of the scaffolds exhibited substantial burst
release within the first 24 hr, in agreement with release profiles observed for metronidazole
from other delivery platforms10,28. In congruence with in vitro data, metronidazole release
from Scaffolds A, B, and C was best modeled by the Higuchi, Korsmeyer-Peppas, and
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Peppas-Sahlin kinetic models. All three models have previously been used to adequately
describe drug release from polymeric matrices, suggesting the 3D printed silicone scaffolds
can be modeled similarly to polymeric matrix systems.
The Higuchi model describes drug release from matrix systems via diffusioncontrolled release and relies on the following assumptions: (i) initial drug concentration is
much higher than solubility drug concentration, (ii) drug diffusion takes place in one
dimension (edge effects are negligible), (iii) drug particles are much smaller than the
delivery system, (iv) drug diffusivity is constant, and (v) perfect sink conditions exist in the
release environment40. The Korsmeyer-Peppas model is a semi-empirical model that
utilizes the first 60% of the drug release curve to determine the mechanism of drug release
using the value of the release exponent, 𝑛40.
For all scaffolds, the release exponent indicated anomalous transport, as the
exponents varied between 0.45 and 0.89. This suggested that the mechanism of drug release
is a combination of Fickian diffusion and polymer relaxation, which resulted in the release
data being fit to the Peppas-Sahlin model43. This semi-empirical model uses two terms to
isolate the drug transport attributed to either Fickian diffusion or polymer relaxation. For
all scaffolds, 𝑘𝑑 was much greater than 𝑘𝑟 indicating that the main mechanism of transport
of metronidazole from the silicone scaffolds is Fickian diffusion. Additionally, all scaffolds
exhibited a negative 𝑘𝑟 , indicating that polymer chain relaxation is insignificant in the
release of metronidazole from silicone54.
For comparison, we evaluated the Weibull model as an additional candidate to
describe metronidazole release from 3D printed scaffolds. The Weibull model is a general
empirical equation that has been widely applied to drug release across dosage forms.
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However, it is limited in its ability to provide comparisons between in vivo and in vitro
release and lacks many parameters that can be related to dissolution rate42. Drug release
from all three scaffolds was adequately modeled with R2 > 0.98.
To better understand the relationship between cumulative metronidazole release
and curing condition, the compressive strength of the metronidazole-containing scaffolds
was evaluated. Compressive strength was evaluated immediately post-cure and following
immersion in SVF for 24 hr and 14 d to help evaluate changes in the mechanical integrity
of the scaffolds, which may be experienced in the vaginal environment. One of the most
striking observations was that both blank and metronidazole-containing scaffolds showed
differences in compressive strength between post-cure and 14 d groups, and in particular
in both the axial and radial directions for Scaffold A, and to a lesser extend for Scaffold B.
In contrast, lesser to negligible differences were observed as a function of immersion
duration for Scaffold C. These results support that the shorter duration of or hardening
during the curing process may have impacted the mechanical integrity of both blank and
metronidazole-containing scaffolds, in particular after longer-term exposure to SVF.
For the metronidazole-containing scaffolds, the most evident increase in
compressive strength between the post-cure and 14 d immersion conditions was seen in
Scaffold A (cured for 4 hr at 50oC followed by 72 hr at 4oC). In comparison, metronidazolecontaining Scaffold B (cured for 4 hr at 50oC followed by 24 hr desiccation at room
temperature) had a more attenuated response in the axial and radial directions, while
Scaffold C (cured for 24 hr at 50oC) exhibited negligible effect between these immersion
conditions. Between post-cure and 14 d immersion in SVF, the load required to axially
compress metronidazole-containing Scaffold A increased 6.4-fold, while increasing 6.2-
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and 1.5-fold for Scaffolds B and C. Similar trends were observed in the load needed to
radially compress metronidazole-containing scaffolds with Scaffold A increased 20-fold
following 14 d in SVF, while Scaffolds B and C increased by 5- and 1.3-fold, respectively.
Considering these observations, we suggest that the shorter curing duration of 4 hr
may leave scaffolds more mechanically susceptible to compression (e.g., potentially less
dense, more porous) than scaffolds cured for 24 hr, perhaps by enabling salts and proteins
in SVF to penetrate the scaffolds and impact the mechanical strength. Conversely,
depending on structure, metronidazole release may have been more rapid from scaffolds
processed with shorter cure durations. Over 14 d immersion in SVF, the metronidazole
released from the scaffold may further enable salts in SVF to diffuse into the scaffold
leading to an increase in compressive strength. In future work we seek to investigate this
relationship more thoroughly to better understand how structural features may impact
mechanical integrity after different durations in physiologically relevant environments.
In addition to differences in the load required for compression, all blank and
metronidazole-containing scaffolds, demonstrated an increase in Young’s modulus
between post-cure and 14 d immersion in SVF in the axial direction. Interestingly, Scaffold
A showed the greatest cumulative drug release over 14 days, while also exhibiting the
largest compressive strength and Young’s modulus of all metronidazole-containing
scaffolds. After 14 days immersed in SVF, the compressive strength and Young’s Modulus
(axially and radially) of the scaffolds decreased from Scaffold A to B to C (Figures 6-8),
while the cumulative drug release decreased from Scaffold A to B to C (Figure 2). This
trend further supports a potential relationship between drug release and scaffold

26

curing/structure, particularly over longer durations in a physiologically relevant
environment.
Another, and potentially more significant observation was seen by the decrease in
compressive strength with the inclusion of metronidazole into the scaffold formulations.
The load required to compress blank scaffolds was ~ 8-, 12-, and 18-fold higher (axially)
and ~ 21-, 25-, and 30-fold higher (radially) for Scaffolds A, B, and C, respectively, than
that needed for similar compression of metronidazole-containing (A, B, or C) scaffolds.
These results suggest that metronidazole – at this concentration – may somewhat weaken
scaffolds to compression. Yet despite the 8 to 30-fold decrease in compressive strength
with the inclusion of metronidazole, the resulting scaffolds have compression strength
similar to the EVA-R intravaginal ring45 and TFV-HPEU 20 rings44, that have compressive
loads between 1 and 1.25 N when compressed by 20% of their original outer diameter45.
Similarly, uniaxial mechanical testing of TFV-HPEU IVRs resulted in a required
compressive load less than 1 N to compress rings by 1 mm44. Given these comparisons, the
mechanical strength of these 3D printed scaffolds suggests that they may be effective for
drug release, while having suitable mechanical properties to be inserted and applied for
intravaginal applications45,55-58.
Longer term, we propose that a platform that can sustain the delivery of both
antibiotics and new biologics may enable an approach to immediately decrease infection
and subsequently restore female reproductive health. With further development, the
proposed core-shell scaffold design could be designed to prevent the recurrence of BV by
returning vaginal pH below 4.5 and thus preventing the growth of pathogens such as G.
vaginalis. Next steps include developing printable formulations that incorporate biologics
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and evaluating the associated release mechanisms. This study represents a key step towards
this goal, focusing on the potential effect of fabrication parameters on active agent release.
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APPENDIX

FIGURE 1 - Cross-sectional and isometric view of tested 3D-printed scaffold design.
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FIGURE 2 - Metronidazole release from 3D printed scaffolds using three replicates. (A)
Short-term release over 24 hr. (B) Long-term release over 14 d. After 24 hr (Scaffold B
and C: p ≤ 0.05) and 14 d (Scaffold B, C: p ≤ 0.05; p ≤ 0.01), Scaffold A had higher release
than Scaffold B and C; release from Scaffolds B and C were similar (p > 0.05). Error bars
represent standard deviation.
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FIGURE 3 - Metronidazole release from Scaffold A fitted to A) Zero order kinetic, B) First
order kinetic, C) Higuchi, D) Korsmeyer-Peppas, E) Hixson Crowell, and F) Peppas-Sahlin
models. The equation of best fit line and R2 values, representing the adequacy of the fit,
are shown on each plot.
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FIGURE 4 - Metronidazole release from Scaffold B fitted to A) Zero order kinetic, B) First
order kinetic, C) Higuchi, D) Korsmeyer-Peppas, E) Hixson Crowell, and F) Peppas-Sahlin
models. The equation of best fit line and R2 values, representing the adequacy of the fit,
are shown on each plot.
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FIGURE 5 - Metronidazole release from Scaffold C fitted to A) Zero Order kinetic, B)
First Order kinetic, C) Higuchi, D) Korsmeyer-Peppas, E) Hixson Crowell, and F) PeppasSahlin models. The equation of best fit line and R2 values, representing the adequacy of
the fit, is shown on each plot.
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FIGURE 6 - Blank silicone and metronidazole-containing scaffolds were evaluated under
20% axial compression as a function of curing condition (Scaffolds A, B, and C),
immediately post-cure and after 24 hr and 14 d in SVF. Load is shown as a function of
axial compression of (A-C) blank scaffolds A, B, and C and (D-F) metronidazolecontaining scaffolds A, B, and C. Mechanical testing was performed using five replicates
per curing condition. Statistical significance between experimental groups, as calculated
by one-way ANOVA, is represented by *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤
0.0001. Please note y-axes scale differences between blank and metronidazole-containing
scaffolds.
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FIGURE 7 - Blank silicone and metronidazole-containing scaffolds were evaluated under
25% radial compression as a function of curing condition (Scaffolds A, B, and C),
immediately post-cure and after 24 hr and 14 d in SVF. Load is shown as a function of
radial compression of (A-C) blank scaffolds A, B, and C and (D-F) metronidazolecontaining scaffolds A, B, and C. Mechanical testing was performed using five replicates
per curing condition. Statistical significance between experimental groups, as calculated
by one-way ANOVA, is represented by *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤
0.0001. Please note y-axes scale differences between blank and metronidazole-containing
scaffolds.
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FIGURE 8 - Young’s modulus of (A) blank and (B) metronidazole-containing scaffolds
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TABLE I
CORRELATION VALUES AND RATE CONSTANTS OF EACH MODEL FOR
SCAFFOLDS A, B, AND C.
Model
Zero Order Kinetic Model
First Order Kinetic Model
Higuchi Square Root Model

Korsmeyer-Peppas Model

Peppas-Sahlin Model

Hixson-Crowell Model

A
k = 0.2129
R2 = 0.6862
k = 0.0023
R2 = 0.9438
k = 3.125
R2 = 0.9918
k = 3.573
n = 0.4740
R2 = 0.9931
kd = 2.378
kr = -0.2390
m = 0.6082
R2 = 0.9990
k = 0.0009
R2 = 0.8224
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Scaffold
B
k = 0.1547
R2 = 0.7667
k = 0.0015
R2 = 0.9494
k = 2.254
R2 = 0.9955
k = 2.078
n = 0.5158
R2 = 0.9959
kd = 1.453
kr = -0.0107
m = 0.6293
R2 = 0.9990
k = 0.0006
R2 = 0.8450

C
k = 0.1263
R2 = 0.7699
k = 0.0012
R2 = 0.9442
k = 1.840
R2 = 0.9954
k = 1.690
n = 0.5164
R2 = 0.9958
kd = 1.274
kr = -0.0091
m = 0.6090
R2 = 0.9980
k = 0.0005
R2 = 0.8304
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